Arabic Arabic English English French French German German
dark

FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

FDA approves Keytruda for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by HFACULTY News. Publisher: FDA Press Releases RSS Feed Click this link to read the full content from the Publisher Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Local action to tackle coronavirus

Next Post

COVID-19 media update, 30 June

Related Posts
Total
0
Share